Dr. Gregory T. Armstrong on Improved Outcomes for Childhood Cancer Survivors

The FDA approved tovorafenib for certain patients with relapsed or refractory pediatric low-grade glioma.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The FDA granted LSTA1 rare pediatric disease designation for the treatment of osteosarcoma.

In this episode of "The Vitals," Ellen Miller, MSN, FNP-BC, talks about meeting a patient who realized she wanted to get pregnant after undergoing chemoradiation as a teenager.

A treatment for NTRK-positive locally advanced or metastatic solid tumors, repotrectinib, is currently under priority review by the FDA and may address a high unmet medical need.

The NCCN has published its first set of treatment recommendations patients with for neuroblastoma.